Publications

2021

Nutt WS, Srivastava SSpecial delivery! CAR-T cells transport RN7SL1 to the tumor microenvironment. Trends Mol Med. 2021 Nov;27(11):1019-1021. 

Le Q, Castro S, Tang T, Loeb AM, Hylkema T, McKay CN, Perkins L, Srivastava S, Call L, Smith J, Leonti A, Ries R, Pardo L, Loken MR, Correnti C, Fiorenza S, Turtle CJ, Riddell SR, Tarlock K, Meshinchi S. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid LeukemiaClinical Cancer Research. 2021 Oct 16; 27(20): 5718-5730.

Veatch J, Singhi N, Srivastava S, Szeto J, Jesernig B, Stull SM, Fitzgibbon M, Sarvothama M, Yechan-Gunja S, James S, Riddell SR. Therapeutic cancer vaccination targeting antigens and adjuvant signals to lymphoid tissues using genetically modified T cellsJournal of Clinical Investigation. 2021 Aug 16; 131(16): e144195.

*Srivastava S, Furlan S, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS, Garrison S, Specht JM, Lee SM, Amezquita RA, Voillet V, Muhunthan V, Yechan-Gunja S, Pillai SPS, Rader C, Houghton AM, Pierce RH, Gottardo R, Maloney DG, Riddell SR. Immunogenic chemotherapy enhances recruitment of CAR-T cells to solid tumors and improves anti-tumor efficacy when combined with checkpoint blockade. Cancer Cell. 2021 Feb 8;39(2):193-208. *Corresponding author. Presentation Video

2019

Srivastava S*, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, Smythe KS, Dudakov JA, Pierce RH, Rader C, Riddell SR. Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. Cancer Cell. 2019 Mar 18; 3(35): 489-503. *Corresponding author.

2018

Srivastava S, Riddell SR. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy. Journal of Immunology. 2018 Jan; 200(2): 459-468. *One of JI’s Top 20 most downloaded article in 2018.

2016

Paszkiewicz PJ, Fräβle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, Sadelain M, Liu L, Jensen MC, Riddell SR, Busch DH. Targeted antibody-mediated depletion of CD19 CAR-T cells permanently reverses B cell aplasia. Journal of Clinical Investigation. 2016 Nov; 126(11): 4262-72.

2015

Srivastava S, Riddell SR. Engineering CAR-T Cells: Design Concepts. Trends in Immunology. 2015 Aug; 36(8): 494-502.

Buechler MB, Gessay GM, Srivastava S, Campbell DJ, Hamerman JA. Hematopoietic and nonhematopoietic cells promote Type I interferon- and TLR7-dependent monocytosis during low-dose LCMV infection. Eur J Immunol. 2015 Nov; 45(11): 3064-72.

2014

Smigiel KS*, Srivastava S*, Stolley JM, Campbell DJ. Regulatory T cell homeostasis: steady-state maintenance and modulation during inflammation. Immunological Reviews. 2014 May; 259(1): 40-59. *These authors contributed equally.

Srivastava S, Koch LK, Campbell DJ. IFNαR signaling in effector but not regulatory T cells is required for immune dysregulation during type I IFN-dependent inflammatory disease. Journal of Immunology. 2014 Sep; 193(6): 2733-42.

Smigiel KS, Richards E, Srivastava S, Thomas KR, Klonowski KD, Campbell DJ. CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets. Journal of Experimental Medicine. 2014 Jan; 211(1): 121-136.

Srivastava S, Koch MA, Pepper M, Campbell DJ. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. Journal of Experimental Medicine, 2014 May; 211(5): 961-74.

2012

Koch MA, Thomas KN, Perdue NR, Smigiel KS, Srivastava S, Campbell DJ. T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor B2. Immunity. 2012 Sep; 37(3): 501-10.

2010

Srivastava S, Macaubas C, Deshpande C, Alexander HC, Chang S, Sun Y, Lee T, Begovich A, Mellins ED. Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis. Clinical Immunology. 2010 Aug; 136(2): 257-68.